Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb randomized, placebo-controlled, double-blind study of FBR-002 in hospitalized COVID-19 patients needing supplemental oxygen
2022-002724-12Phase 2Terminated
- Sponsor
- Fabentech
- Start
- Oct 2022
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of anti SARS-CoV-2 equine hyperimmune serum in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Fabentech. Started Oct 2022; status: terminated.
02
Drugs
anti SARS-CoV-2 equine hyperimmune serum
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-002724-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002724-12.